-
Je něco špatně v tomto záznamu ?
Analysis of expression, epigenetic, and genetic changes of HNF1B in 130 kidney tumours
M. Bártů, J. Hojný, N. Hájková, R. Michálková, E. Krkavcová, L. Hadravský, L. Kleissnerová, QH. Bui, I. Stružinská, K. Němejcová, O. Čapoun, M. Šlemendová, P. Dundr
Jazyk angličtina Země Velká Británie
Typ dokumentu časopisecké články, práce podpořená grantem
Grantová podpora
NV17-28404A
MZ0
CEP - Centrální evidence projektů
Digitální knihovna NLK
Plný text - Článek
NLK
Directory of Open Access Journals
od 2011
Free Medical Journals
od 2011
Nature Open Access
od 2011-12-01
PubMed Central
od 2011
Europe PubMed Central
od 2011
ProQuest Central
od 2011-01-01
Open Access Digital Library
od 2011-01-01
Open Access Digital Library
od 2011-01-01
Health & Medicine (ProQuest)
od 2011-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2011
Springer Nature OA/Free Journals
od 2011-12-01
- MeSH
- epigeneze genetická genetika MeSH
- epigenomika metody MeSH
- hepatocytární jaderný faktor 1-beta genetika MeSH
- karcinom z renálních buněk genetika patologie MeSH
- ledviny patologie MeSH
- lidé MeSH
- mutační analýza DNA metody MeSH
- nádory ledvin genetika patologie MeSH
- promotorové oblasti (genetika) genetika MeSH
- zárodečné mutace genetika MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
Hepatocyte nuclear factor 1 beta (HNF1B) is a transcription factor which plays a crucial role in nephronogenesis, and its germline mutations have been associated with kidney developmental disorders. However, the effects of HNF1B somatic exonic mutations and its role in the pathogenesis of kidney tumours has not yet been elucidated. Depending on the type of the tumour HNF1B may act as a tumour suppressor or oncogene, although the exact mechanism by which HNF1B participates in the process of cancerogenesis is unknown. Using an immunohistochemical approach, and methylation and mutation analysis, we have investigated the expression, epigenetic, and genetic changes of HNF1B in 130 cases of renal tumours (121 renal cell carcinomas, 9 oncocytomas). In the subset of clear cell renal cell carcinoma (ccRCC), decreased HNF1B expression was associated with a higher tumour grade and higher T stage. The mutation analysis revealed no mutations in the analysed samples. Promoter methylation was detected in two ccRCCs and one oncocytoma. The results of our work on a limited sample set suggest that while in papillary renal cell carcinoma HNF1B functions as an oncogene, in ccRCC and chRCC it may act in a tumour suppressive fashion.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21012037
- 003
- CZ-PrNML
- 005
- 20210507104401.0
- 007
- ta
- 008
- 210420s2020 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1038/s41598-020-74059-z $2 doi
- 035 __
- $a (PubMed)33051485
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Bártů, Michaela $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Studnickova 2, 12800, Prague 2, Czech Republic. michaela.bartu@vfn.cz
- 245 10
- $a Analysis of expression, epigenetic, and genetic changes of HNF1B in 130 kidney tumours / $c M. Bártů, J. Hojný, N. Hájková, R. Michálková, E. Krkavcová, L. Hadravský, L. Kleissnerová, QH. Bui, I. Stružinská, K. Němejcová, O. Čapoun, M. Šlemendová, P. Dundr
- 520 9_
- $a Hepatocyte nuclear factor 1 beta (HNF1B) is a transcription factor which plays a crucial role in nephronogenesis, and its germline mutations have been associated with kidney developmental disorders. However, the effects of HNF1B somatic exonic mutations and its role in the pathogenesis of kidney tumours has not yet been elucidated. Depending on the type of the tumour HNF1B may act as a tumour suppressor or oncogene, although the exact mechanism by which HNF1B participates in the process of cancerogenesis is unknown. Using an immunohistochemical approach, and methylation and mutation analysis, we have investigated the expression, epigenetic, and genetic changes of HNF1B in 130 cases of renal tumours (121 renal cell carcinomas, 9 oncocytomas). In the subset of clear cell renal cell carcinoma (ccRCC), decreased HNF1B expression was associated with a higher tumour grade and higher T stage. The mutation analysis revealed no mutations in the analysed samples. Promoter methylation was detected in two ccRCCs and one oncocytoma. The results of our work on a limited sample set suggest that while in papillary renal cell carcinoma HNF1B functions as an oncogene, in ccRCC and chRCC it may act in a tumour suppressive fashion.
- 650 _2
- $a karcinom z renálních buněk $x genetika $x patologie $7 D002292
- 650 _2
- $a mutační analýza DNA $x metody $7 D004252
- 650 _2
- $a epigeneze genetická $x genetika $7 D044127
- 650 _2
- $a epigenomika $x metody $7 D057890
- 650 _2
- $a zárodečné mutace $x genetika $7 D018095
- 650 _2
- $a hepatocytární jaderný faktor 1-beta $x genetika $7 D051539
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a ledviny $x patologie $7 D007668
- 650 _2
- $a nádory ledvin $x genetika $x patologie $7 D007680
- 650 _2
- $a promotorové oblasti (genetika) $x genetika $7 D011401
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Hojný, Jan $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Studnickova 2, 12800, Prague 2, Czech Republic
- 700 1_
- $a Hájková, Nikola $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Studnickova 2, 12800, Prague 2, Czech Republic
- 700 1_
- $a Michálková, Romana $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Studnickova 2, 12800, Prague 2, Czech Republic
- 700 1_
- $a Krkavcová, Eva $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Studnickova 2, 12800, Prague 2, Czech Republic
- 700 1_
- $a Hadravský, Ladislav $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Studnickova 2, 12800, Prague 2, Czech Republic
- 700 1_
- $a Kleissnerová, Lenka $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Studnickova 2, 12800, Prague 2, Czech Republic
- 700 1_
- $a Bui, Quang Hiep $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Studnickova 2, 12800, Prague 2, Czech Republic
- 700 1_
- $a Stružinská, Ivana $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Studnickova 2, 12800, Prague 2, Czech Republic
- 700 1_
- $a Němejcová, Kristýna $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Studnickova 2, 12800, Prague 2, Czech Republic
- 700 1_
- $a Čapoun, Otakar $u Department of Urology, General University Hospital in Prague, 12808, Prague, Czech Republic
- 700 1_
- $a Šlemendová, Monika $u Department of Urology, General University Hospital in Prague, 12808, Prague, Czech Republic
- 700 1_
- $a Dundr, Pavel $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Studnickova 2, 12800, Prague 2, Czech Republic. pavel.dundr@vfn.cz
- 773 0_
- $w MED00182195 $t Scientific reports $x 2045-2322 $g Roč. 10, č. 1 (2020), s. 17151
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/33051485 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20210420 $b ABA008
- 991 __
- $a 20210507104359 $b ABA008
- 999 __
- $a ok $b bmc $g 1650422 $s 1132416
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 10 $c 1 $d 17151 $e 20201013 $i 2045-2322 $m Scientific reports $n Sci Rep $x MED00182195
- GRA __
- $a NV17-28404A $p MZ0
- LZP __
- $a Pubmed-20210420